Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7163153 | 0.93 | MAOA (0.52) | SIGMAR1MAOATDP1HTR3AMAOB | |
| SCHEMBL9428184 | 0.91 | SIGMAR1 (0.52) | SIGMAR1MAOAMAOBL3MBTL1 | |
| SCHEMBL7166792 | 0.91 | SIGMAR1 (0.52) | SIGMAR1MAOAMAOBL3MBTL1 | |
| SCHEMBL9671296 | 0.91 | SIGMAR1 (0.52) | SIGMAR1MAOAMAOBL3MBTL1 | |
| SCHEMBL15530118 | 0.91 | SIGMAR1 (0.52) | SIGMAR1MAOAMAOBL3MBTL1 | |
| Formic Acid SCHEMBL30734367 | 0.88 | HDAC3 (0.46) | SIGMAR1MAOATDP1HTR3AHDAC3 | |
| SCHEMBL129338 | 0.85 | TDP1 (0.52) | SIGMAR1MAOATDP1MAOBHTR2A | |
| SCHEMBL11151727 | 0.82 | FFAR1 (0.50) | — | |
| SCHEMBL11593970 | 0.80 | SIGMAR1 (0.52) | SIGMAR1MAOAMAOBHTR2AIDO1 | |
| SCHEMBL11149070 | 0.79 | TAAR1 (0.48) | SIGMAR1HTR2AIDO1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0804464-B1 | AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS | CORVAS INT INC (US) | 2002-05-08 | — | — | EP | claimed |
| US-6011158-A | PEPTIDE ALDEHYDE COMPOUNDS HAVING ARGININE OR ARGININE MIMICS AT P1 AND PYRIDONE, PYRIMIDONE, OR URACIL GROUPS AS PART OF THE PEPTIDE BACKBONE. THESE COMPOUNDS ARE POTENT INHIBITORS OF THROMBIN IN VIVO AND IN VITRO. | CORVAS INTERNATIONAL, INC. (US) | 2000-01-04 | — | — | US | claimed |
| CN-1169730-A | Aromatic heterocyclic derivatives as enzyme inhibitors | CORVAS INT INC (US) | 1998-01-07 | — | — | CN | claimed |
| EP-0804464-A1 | AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1997-11-05 | — | — | EP | claimed |
| WO-1996018644-A9 | AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS | — | 1996-08-01 | — | — | WO | claimed |
| WO-1996018644-A1 | AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1996-06-20 | — | — | WO | claimed |
| WO-2026044165-A1 | STEREOISOMERIC FUSED-CYCLOPROPYL ANALOGUES OF 4-HYDROXYCYCLOHEXANE CARBOXAMIDES AND RELATED COMPOUNDS | DORN II GERALD W (US) | 2026-02-26 | — | — | WO | disclosed |
| CN-116199610-B | Compounds having glycosidase inhibitory activity, salts and hydrates thereof and use thereof | 中国科学院化学研究所 | 2025-03-25 | — | — | CN | disclosed |
| US-12053459-B2 | CDK2 inhibitors and methods of using the same | CEDILLA THERAPEUTICS, INC. (MA) | 2024-08-06 | — | — | US | disclosed |
| EP-4358954-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117466942-A | Chiral secondary phosphine oxide compound, chiral quinazolinone/pyrimidinone ring derivative based on chiral secondary phosphine oxide compound and application of chiral quinazolinone/pyrimidinone ring derivative | 中山大学 | 2024-01-30 | — | — | CN | disclosed |
| CN-114940694-B | Steroid compound, preparation method thereof and application thereof in treatment of tumors related to p53 mutation | 云南大学 | 2023-06-09 | — | — | CN | disclosed |
| CN-116199610-A | Compounds having glycosidase inhibitory activity, salts and hydrates thereof and use thereof | 中国科学院化学研究所 | 2023-06-02 | — | — | CN | disclosed |
| EP-0078145-A1 | Resolution of racemic 5-phenyl-2-pentanol | PFIZER INC. (US) | 1983-05-04 | — | — | EP | disclosed |
| US-4356182-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-10-26 | — | — | US | disclosed |
| US-4316905-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-02-23 | — | — | US | disclosed |
| US-4301164-A | FOR USE AS ANTIULCER AGENTS, HYPOTENSIVE AGENTS, ANTITHROMBOSIC AGENTS | TORAY INDUSTRIES, INC. (JP) | 1981-11-17 | — | — | US | disclosed |
| US-4291040-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1981-09-22 | — | — | US | disclosed |
| EP-0024943-A1 | 5,6,7-Trinor-4,8-inter-m-phenylene PGI2 derivatives and pharmaceutical compositions containing them | TORAY INDUSTRIES, INC. (JP) | 1981-03-11 | — | — | EP | disclosed |
| US-3931196-A | Phosphinolines and phosphindolines | MONASH UNIVERSITY (AU) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12053459-B2 | CDK2 inhibitors and methods of using the same | CDK2, CDK20, CDK2AP2 | SIGMAR1 4780/4885MAOA 3268/4885TDP1 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.